Integra LifeSciences(IART) - 2023 Q3 - Earnings Call Presentation

Third Quarter 2023 Net Debt Reconciliation Revenue $1.541B-$1.547B | --- | --- | --- | |--------------|-------------------------------------------------------|---------------------| | Neurosurgery | Q3 2023 Growth and Performance Drivers2 \nInstruments | International | | 8.0% | 5.0% | Double-Digit growth | Private Label 22.9% Wound Reconstruction 77.1% IART Q3 2023 Earnings Presentation Note: Organic growth, adj. gross margin, adj. EBITDA margin and adj. EPS are non-GAAP financial measures. $193.1 IART Q3 ...